Leading specialists will address the latest advances in diagnosis, genetics, and therapies for neuromuscular diseases
Santander will host the 1st Northwest Neuromuscular Disease Update Conference on May 29 and 30, 2026, a scientific meeting that will bring together neurologists and neuromuscular disease specialists from hospitals across northern Spain. The goal is to share the latest clinical, diagnostic, and therapeutic developments in this field.
Organized as an in‑person event, the conference aims to promote knowledge exchange among professionals and update the management of complex neuromuscular disorders, incorporating recent advances in genetics, targeted therapies, and differential diagnosis.
The meeting will begin on Friday, May 29 at 17:15, with a welcome session led by Dr. Jorge Madera and Dr. Ana Lara Pelayo from Marqués de Valdecilla University Hospital. The scientific program will follow, including presentations on myasthenia gravis and new targeted therapies by Ana Lara Pelayo, as well as an update on immune‑mediated neuropathies beyond CIDP, presented by César Ramón from San Agustín University Hospital.
The afternoon will continue with highly relevant topics such as genetic updates and therapeutic perspectives in amyotrophic lateral sclerosis (ALS), presented by Jorge Madera, and newborn screening and therapeutic switching strategies in adults with spinal muscular atrophy (SMA), led by Daniel Santirso from the Central University Hospital of Asturias.
On Saturday, May 30, the program will resume with sessions focused on clinical practice. Adrián Ares, from León University Hospital, will present an update on inflammatory myopathies, while Germán Morís, from the Central University Hospital of Asturias, will address dropped head syndrome from a semiological and differential diagnosis perspective.
The second day will also include clinical debate, a Q&A session, the “Neuromuscular Challenge”, and will conclude with the awards ceremony and official closing.
The conference is supported by healthcare and pharmaceutical partners committed to research and the development of new therapies for these conditions, including Argenx and Janssen.
Registration is available through this link: https://forms.gle/cpjZJXfeojhEPrWn8
